USPTO Examiner BARRON SEAN C - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17137557CONTROLLED AGGREGATION OF CELLSDecember 2020July 2024Abandon4220NoNo
17129058PROCESS FOR PRODUCING FUEL USING TWO FERMENTATIONSDecember 2020August 2023Allow3201NoNo
17128654CLEARING REAGENT FOR BIOLOGICAL MATERIAL, AND USE THEREOFDecember 2020February 2025Abandon5040YesNo
17128303METHOD FOR MAKING BIOLOGICAL MATERIAL TRANSPARENT AND USE THEREOFDecember 2020February 2025Abandon5040YesNo
17253118EVALUATION METHOD FOR GENOMIC ABNORMALITIES IN CELLSDecember 2020May 2025Abandon5311NoNo
17111147SOFT TISSUE REPAIR AND METHODS FOR PREPARING SAMEDecember 2020October 2023Allow3511NoNo
17111390B-CELL CULTIVATION METHODDecember 2020November 2023Abandon3510NoNo
17057678ANTIBACTERIAL PHAGE, THERAPEUTIC COMPOSITION, BACTERICIDAL AGENT, FOOD, BACTERIA IDENTIFICATION KIT, THERAPEUTIC COMPOSITION MANUFACTURING METHOD, BACTERIA ELIMINATION METHOD, BACTERIA IDENTIFICATION METHOD, AND ANIMAL THERAPEUTIC METHODNovember 2020March 2024Abandon4010NoNo
17056527Suppression of Bone Cancer-induced AllodyniaNovember 2020January 2024Allow3810NoNo
17099122METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL AND PROLIFERATION OF ENDOTHELIAL CELLS AND STIMULATING ANGIOGENSISNovember 2020October 2023Allow3510YesNo
17097987TISSUE FRAGMENTNovember 2020October 2023Abandon3510NoNo
17091286DETERGENT COMPOSITIONNovember 2020January 2024Abandon3811NoNo
17084929RECOMBINANT ORGANISMS AND METHODS FOR PRODUCING GLYCOMOLECULES WITH HIGH GLYCAN OCCUPANCYOctober 2020June 2024Abandon4301NoNo
17083531Compositions and methods for stable isotope labelling of biological compoundsOctober 2020March 2025Abandon5330NoNo
17082166PHOTOTROPHIC PURIFICATION OF HYDROGEN SULFIDE CONTAINING STREAMSOctober 2020June 2024Allow4302YesNo
17081983APPARATUSES AND METHODS USING NANOSTRAWS TO DELIVER BIOLOGICALLY RELEVANT CARGO INTO NON-ADHERENT CELLSOctober 2020January 2024Allow3911NoNo
17075116SELECTIVE DELIVERY OF MATERIAL TO CELLSOctober 2020July 2023Allow3210NoNo
17042751Application of Lentiviral Vector EF1alpha Promoter for Optimising ABCD1 Gene Expression to Treat AdrenoleukodystrophySeptember 2020April 2024Allow4311NoNo
17031206BIOARTIFICIAL PANCREASSeptember 2020October 2023Abandon3701NoNo
17024684METHOD FOR PREPARING BONE GRAFT COMPOSITION AND BONE GRAFT COMPOSITIONSeptember 2020December 2023Abandon3911NoNo
17015813MICROTOME SECTIONABLE GEL SUPPORT STRUCTURE AND METHODSSeptember 2020June 2023Allow3410NoNo
17013454SYSTEMS AND METHODS FOR SEEDING CELL CULTURES IN A MICROFLUIDIC DEVICESeptember 2020May 2023Allow3211YesNo
17004857COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASESAugust 2020September 2024Abandon4830NoNo
17005118RUSALATIDE ACETATE COMPOSITIONSAugust 2020December 2023Allow3921YesNo
16989554METHODS OF GENERATING HUMAN INNER EAR SENSORY EPITHELIA AND SENSORY NEURONSAugust 2020April 2024Allow4530YesNo
16933253RAPID SPERM SEPARATION BASED ON SPERM MORPHOLOGY AND MOTILITYJuly 2020July 2023Abandon3610NoNo
16927068PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOFJuly 2020February 2025Abandon5540NoNo
16922493COMPOSITIONS AND METHODS FOR MAXIMIZING MALONYL-COA IN E. COLIJuly 2020April 2024Abandon4530YesNo
16909616ENHANCED DIFFERENTIATION OF MESENCHYMAL STEM CELLSJune 2020October 2024Allow5250YesYes
16909806COMPOSITIONS AND METHODS FOR MULTIPLEXED QUANTITATIVE ANALYSIS OF CELL LINEAGESJune 2020April 2024Abandon4601NoNo
16765196MICROBIAL HOST CELLS FOR PRODUCTION OF STEVIOL GLYCOSIDESMay 2020January 2023Abandon3201NoNo
16878510METHOD FOR ASSESSMENT OF HEPATIC FUNCTION AND PORTAL BLOOD FLOWMay 2020January 2024Allow4431YesNo
16856608DENTAL PRETREATMENT MATERIAL AND DENTAL TISSUE REGENERATION KITApril 2020October 2022Abandon3010NoNo
16853865Methods for Fluid Mixing Systems with Laterally Displaced Flexible Drive LinesApril 2020April 2024Allow4821YesNo
16850919DRY MATRIX FOR EMBEDDING VIABLE ESCHERICHIA COLI, METHOD OF MAKING SAME AND USE THEREOFApril 2020March 2024Abandon4740NoNo
16843951Systems and Methods For Isolating Microvessels From Adipose TissueApril 2020October 2023Abandon4221NoNo
16832446APPARATUS AND METHOD OF AIR-SUSPENDED BIOFABRICATION OF TISSUE-ENGINEERED ORGAN CONSTRUCTS AND CONGLOMERATES OF SPHEROIDS, CELLS AND OTHER BIOLOGICAL OBJECTS BY USING MAGNETIC FIELDMarch 2020March 2023Abandon3501NoNo
16651974Isothiocyanate containing Brassicaceae Products and Method of Preparation ThereofMarch 2020September 2024Allow5441YesNo
16825225HIGH POTENCY STABLE FORMULATIONS OF VAGINAL LACTOBACILLUSMarch 2020April 2021Allow1221YesNo
16781764PACKED-BED BIOREACTOR SYSTEMS AND METHODS OF USING THE SAMEFebruary 2020October 2024Abandon5641NoNo
16774211Method and System for Treatment of Microorganisms during Propagation, Conditioning, Fermentation, and Preservation Using LAE and Selected AdditivesJanuary 2020November 2024Abandon5840NoYes
16625579ENGINEERED AND FULLY-FUNCTIONAL CUSTOMIZED GLYCOPROTEINSDecember 2019October 2023Allow4521YesNo
16717411DRY MATRIX FOR EMBEDDING VIABLE ESCHERICHIA COLI, METHOD OF MAKING SAME AND USE THEREOFDecember 2019March 2024Abandon5140NoNo
16715905COMPOSITIONS OF CITRULLINEDecember 2019June 2023Abandon4211NoNo
16621528CORNEAL ENDOTHELIAL CELL MARKER AND USE THEREOFDecember 2019July 2023Allow4320NoNo
16707804METHODS AND SYSTEMS FOR CONVERSION OF BIOMASS MATERIALS INTO BIOFUELS AND BIOCHEMICALSDecember 2019January 2024Abandon4940YesNo
16705344CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOFDecember 2019January 2023Allow3821NoNo
16705314CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOFDecember 2019June 2022Allow3110NoNo
16620395METHOD FOR REMOVING UNDIFFERENTIATED PLURIPOTENT STEM CELLSDecember 2019February 2025Allow6021YesNo
16703511Bacterial Growth on Non-Animal Derived MediaDecember 2019March 2025Abandon6060YesNo
16700990CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTUREDecember 2019October 2022Abandon3401NoNo
16700189METHOD FOR TREATING INTESTINAL GLUTAMINE SYNTHETASE ACTIVITY DEFICIENCYDecember 2019October 2022Abandon3511NoNo
16701013CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTUREDecember 2019November 2021Abandon2421NoYes
16698403HUNTER SYNDROME THERAPEUTIC AGENT AND TREATMENT METHODNovember 2019August 2022Abandon3230NoNo
16617998MATRIX OF RICE HUSK SILICA FOR IMMOBILIZING ENZYME AND USES THEREOFNovember 2019February 2024Abandon5131NoNo
16698666PROVIDENT METHOD OF CELLULASES ENZYMES PRODUCTION BY PENICILLIUM FUNICULOSUM MRJ-16 USING LOW COST MEDIA COMPONENTSNovember 2019August 2021Allow2010NoNo
16616627Nanocone Structure Composite Material for Capturing Cancer Cells, Preparation Method Therefor and Use ThereofNovember 2019March 2024Abandon5231NoNo
16616745MICROFLUIDIC CHIP FOR CIRCULATING TUMOR CELL SEPARATION, CIRCULATING TUMOR CELL SEPARATION METHOD AND COUNTING METHODNovember 2019December 2022Abandon3711NoNo
16616665System and Method for Paper-Based CryopreservationNovember 2019April 2023Allow4021NoNo
16616636A PROCESS TO PREPARE ELEMENTAL SULPHURNovember 2019January 2022Allow2521NoNo
16614819MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASENovember 2019October 2024Allow5951NoNo
16614195DEFOAMER FOR FERMENTER, AND MICROORGANISM FERMENTER USING DEFOAMER FOR FERMENTERNovember 2019September 2022Allow3411NoNo
16612756METHODS AND COMPOSITIONS OF INCORPORATING A BIOACTIVE AGENT AND USE THEREOFNovember 2019December 2021Abandon2631NoNo
16610625BLOOD VESSEL MIMIC AND METHOD FOR CULTURING BLOOD VESSEL MIMICNovember 2019January 2025Abandon6051YesYes
16672056IDENTIFYING STATUS OF MALE FERTILITY BY DETERMINING SPERM CAPACITATION AND COMPANION COLLECTION KITNovember 2019March 2025Abandon6041NoNo
16610325Polymeric Carriers and MethodsNovember 2019September 2022Allow3511NoNo
16664264BIOCIDE COMPOSITIONS COMPATIBLE WITH ENZYME BIOSENSORS AND METHODS OF USE THEREOFOctober 2019December 2023Allow4941YesNo
16500071MEDIA FOR MICROORGANISM CULTURE AND RELATED COMPOSITIONS AND METHODSOctober 2019March 2022Abandon2901NoNo
16496523PERFUSION MEDIUMSeptember 2019October 2023Abandon4931NoNo
16574984Methanothermobacter Thermautotrophicus Strain and Variants ThereofSeptember 2019March 2022Abandon3011NoNo
16574587DEVICES AND METHODS FOR ISOLATING A MIGRATORY CELL POPULATIONSeptember 2019December 2024Allow6051YesNo
16494197METHODS AND COMPOSITIONS FOR MODULATION OF IMMUNE CELLSSeptember 2019March 2024Abandon5441NoNo
16493996A METHOD OF INHIBITING ISOMERIZATION OF A REDUCING SACCHARIDE UPON THERMAL TREATMENTSeptember 2019March 2025Abandon6071YesYes
16570626METHOD FOR SEPARATING MEGAKARYOCYTES AND PLATELETS AND INSTRUMENT FOR SEPARATING MEGAKARYOCYTES AND PLATELETSSeptember 2019December 2022Abandon3920YesNo
16492715RAPID DETECTION OF E. COLI IN A THIN FILM CULTURE DEVICESeptember 2019February 2022Allow2910NoNo
16562529SOLID MEDIUM FOR PRODUCING GLUCOSAMINE AND ITS APPLICATIONSeptember 2019April 2022Allow3111NoNo
16560597COMPOSITIONS AND METHODS FOR IDENTIFYING METABOLICALLY ACTIVE AGENTSSeptember 2019October 2021Allow2511NoNo
16489153TRYPSIN-LIKE SERINE PROTEASES AND USES THEREOFAugust 2019May 2022Allow3310YesNo
16550810MEDICINES FOR TOPIC USE BASED ON SULFATED HYALURONIC ACID AS ACTIVATING OR INHIBITING AGENT OF THE CYTOKINE ACTIVITYAugust 2019August 2021Allow2411YesNo
16549140System, Method, and Composition for Incubating Spores for Use in Aquaculture, Agriculture, Wastewater, and Environmental Remediation ApplicationsAugust 2019May 2022Allow3211NoNo
16549757Bioreactor Paradigm for the Production of Secondary extra-Particle Hyphal MatricesAugust 2019September 2021Allow2500NoNo
16545097DETECTION OF NUCLEASE EDITED SEQUENCES IN AUTOMATED MODULES AND INSTRUMENTSAugust 2019January 2024Allow5321NoNo
16486600TRANSPARENT DISC-SHAPED MICROPARTICLES COATED WITH POLYDOPAMINEAugust 2019July 2022Allow3520YesNo
16542121LINKING METHODS, COMPOSITIONS, SYSTEMS, KITS AND APPARATUSESAugust 2019July 2021Abandon2310NoNo
16541938CELL CULTURE SUBSTRATE HAVING TWO ACRYLATE STRUCTURAL UNITSAugust 2019October 2023Abandon5040YesNo
16541848CELL CULTURE SUBSTRATE COMPRISING A COPOLYMER AND A STRUCTURAL UNITAugust 2019September 2023Abandon4941NoNo
16541897CELL CULTURE SUBSTRATE HAVING A STRUCTURAL UNIT DERIVED FROM FURFURYL (METH) ACRYLATEAugust 2019August 2023Allow4840YesNo
16541989CELL CULTURE SUBSTRATE HAVING AN ACRYLATE STRUCTURAL UNIT AND A MONOMER STRUCTURAL UNITAugust 2019February 2023Allow4220YesNo
16508228CELL CULTURE SUBSTRATE, CULTURE VESSEL, METHOD FOR PRODUCING CELL CULTURE VESSEL, METHOD FOR OBTAINING CELLS AND METHOD FOR CULTURING CELLSJuly 2019February 2023Allow4430YesNo
16453323MICROORGANISMS AND METHODS FOR THE PRODUCTION OF FATTY ACIDS AND FATTY ACID DERIVED PRODUCTSJune 2019November 2021Allow2910NoNo
16446802Methods of Manufacturing and Assembling Cell-Containing BlocksJune 2019May 2022Allow3511YesNo
16436578Biomaterial for SuturingJune 2019May 2021Allow2410NoNo
16467535CELL CULTURE SUBSTRATEJune 2019January 2022Allow3110YesNo
16428560COMPOSITIONS AND METHODS FOR DISRUPTING BIOFILM FORMATION AND MAINTENANCEMay 2019August 2022Allow3822YesNo
16464084MICROORGANISM TEST SYSTEMMay 2019May 2022Abandon3611NoNo
16461397MICROBIAL DETECTION DEVICES INCLUDING ADHESIVE MASKED NUTRIENTS AND METHODS OF USING THE SAMEMay 2019June 2022Allow3721YesNo
16411395PERIPHERAL DIAGNOSTIC METHODS FOR SCREENING ALZHEIMER'S DISEASE USING BETA AMYLOID AND INTERCELLULAR COMMUNICATIONMay 2019May 2021Allow2420NoNo
16349237PROTEASE SENSOR MOLECULESMay 2019November 2023Allow5431YesNo
16407026SYSTEM AND METHOD FOR ORGANOID CULTUREMay 2019August 2022Allow3931YesYes
16348170METHODS FOR CONVECTIVELY-DRIVEN INTRACELLULAR DELIVERYMay 2019September 2021Allow2811NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BARRON, SEAN C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
17
Examiner Affirmed
11
(64.7%)
Examiner Reversed
6
(35.3%)
Reversal Percentile
57.1%
Higher than average

What This Means

With a 35.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
66
Allowed After Appeal Filing
12
(18.2%)
Not Allowed After Appeal Filing
54
(81.8%)
Filing Benefit Percentile
23.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BARRON, SEAN C - Prosecution Strategy Guide

Executive Summary

Examiner BARRON, SEAN C works in Art Unit 1653 and has examined 560 patent applications in our dataset. With an allowance rate of 51.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner BARRON, SEAN C's allowance rate of 51.2% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BARRON, SEAN C receive 2.83 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BARRON, SEAN C is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +34.0% benefit to allowance rate for applications examined by BARRON, SEAN C. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.0% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.8% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 54.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 63.0% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 65.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.